Abstract 4332: Proprotein convertases as target for therapy of pediatric sarcomas

Michele Bernasconi(University of Bern), Beat Schaefer(University Hospital Zurich), Beat Bornhäuser(University Children's Hospital Zurich), Valentina D’Alessandro(University Children's Hospital Zurich), Felix Niggli(University of Zurich)

Cancer Research

April 1, 2012

10.1158/1538-7445.am2012-4332

Cited by 0

Related Papers

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

|Blood|2009|347

PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability

|Cancer Discovery|2017|336

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

|Blood|2014|327

Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance

|Journal of Clinical Investigation|2010|311

<i>IKZF1</i><sup>plus</sup>Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

|Journal of Clinical Oncology|2018|304